Article
Risk of Mortality Prediction Involving Time-Varying Covariates for Patients with Heart Failure Using Deep Learning

Keijiro Nakamura 1,*, Xue Zhou 2,*, Naohiko Sahara 1,*, Yasutake Toyoda 1, Yoshinari Enomoto 1, Hidehiko Hara 1, Mahito Noro 3, Kaoru Sugi 3, Ming Huang 2, Masao Moroi 1, Masato Nakamura 1 and Xin Zhu 4,*,

1 Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan
2 Graduate School of Science and Technology, Nara Institute of Science and Technology, Ikoma 630-0192, Japan
3 Division of Cardiovascular Medicine, Odawara Cardiovascular Hospital, Odawara 250-0873, Japan
4 Graduate Department of Computer and Information Systems, The University of Aizu, Aizuwakamatsu 965-8580, Japan
* Correspondence: keijiro.nakamura@med.toho-u.ac.jp (K.N.); x.zhou@is.naist.jp (X.Z.); zhuxin@u-aizu.ac.jp (X.Z.); Tel.: +81-3-468-1251 (K.N.); +81-242-37-2771 (Xin Zhu)

Abstract: Heart failure (HF) is challenging public medical and healthcare systems. This study aimed to develop and validate a novel deep learning-based prognostic model to predict the risk of all-cause mortality for patients with HF. We also compared the performance of the proposed model with those of classical deep learning- and traditional statistical-based models. The present study enrolled 730 patients with HF hospitalized at Toho University Ohashi Medical Center between April 2016 and March 2020. A recurrent neural network-based model (RNNSurv) involving time-varying covariates was developed and validated. The proposed RNNSurv showed better prediction performance than those of a deep feed-forward neural network-based model (referred as “DeepSurv”) and a multivariate Cox proportional hazard model in view of discrimination (C-index: 0.839 vs. 0.755 vs. 0.762, respectively), calibration (better fit with a 45-degree line), and ability of risk stratification, especially identifying patients with high risk of mortality. The proposed RNNSurv demonstrated an improved prediction performance in consideration of temporal information from time-varying covariates that could assist clinical decision-making. Additionally, this study found that significant risk and protective factors of mortality were specific to risk levels, highlighting the demand for an individual-specific clinical strategy instead of a uniform one for all patients.

Keywords: deep learning; heart failure; mortality; risk prediction; time-varying covariates

1. Introduction
Heart failure (HF) has been significantly associated with mortality, especially among those older than 65 years [1,2]. Japan has a “super-aged” society, and the number of patients with HF was estimated to reach 1.3 million by 2030 [3]. Although a better survival prognosis in Japan than that in Europe had been observed, the length of hospital stays in Japan was approximately three times that in western countries [4]. Simultaneously, HF was a leading cause of hospitalization in Japan, bringing a heavy economic burden to society [5]. Considering these facts, a prognostic prediction model is expected to inform patients and their families about the course of the disease and guide physicians to more optimal treatment and management strategies such as allocation of medical resources in consideration of survival prognosis.

The multivariate Cox proportional hazard (CPH) model [6] is the most frequently used statistical-based method for risk prediction, but its performance is somewhat limited by the linearity of the functional form assumed in the partial hazard (exponential) part [7,8]. By contrast, deep learning-based prediction models can fit and learn more complicated (e.g., non-linearity by activation function) relationships between covariates and outcomes. A fully connected (FC) neural network-based survival prediction model, referred to “DeepSurv”,...
has been proposed by Katzman et al. [9]. It achieved better prediction performances than the CPH model for cancer survival [10] and cardiovascular risk [8], and displayed a workable performance on early triage of critically ill patients with COVID-19 [11].

Despite the widespread use of the CPH model and performance improvement achieved by DeepSurv, the two models only consider invariant covariates but have no ability to learn from time-varying covariates. Although a time-varying CPH model has been proposed to take time-varying covariates into consideration [12], this model deals with the time-dependent issue by simply considering the hazard at time t depending on the value of the time-varying covariate at that time but the regression effect or the weight of the covariate being constant or invariant. In essence, it is similar to a traditional CPH model. Therefore, the model cannot capture the temporal relationship implied in time-varying covariates. Furthermore, the time-varying CPH model requires the dataset to be pre-processed into a so-called “long” format, where each duration is represented in a start and stop view, which is monotonous. In this study, a recurrent neural network (RNN)-based model, referred to as “RNNSurv”, was developed and temporally validated. Temporal validation (or narrow validation) was defined by Moons et al. as follows: “External validation may use participant data collected by the same investigators, typically using the same predictor and outcome definitions and measurements, but sampled from a later period” [13]. The proposed model could learn temporal features from time-varying covariates and fit nonlinear relationship to predict risk of all-cause mortality for patients with HF. RNNSurv demonstrated better performance than CPH and DeepSurv in terms of discrimination, calibration, and ability of risk stratification, especially identifying the patients with high risk of mortality. Patients’ characteristics varied by risk level in view of the stratified risk groups (high risk and other (or low risk)). This study also suggested that significant risk and protective factors of mortality were required to be discussed specific to risk levels.

2. Materials and Methods
2.1. Study Design and Data Collection

The protocol for this retrospective study was prepared in accordance with the Declaration of Helsinki, and the study was approved by the Institutional Review Board and Ethics Committee of Ohashi Medical Center, School of Medicine, Toho University (No. H19031). The data collection was the same as that explained in a previous study [14]. Medical records of patients with HF hospitalized at Toho University Ohashi Medical Center between April 2016 and March 2019 were reviewed by cardiovascular specialists, constituting a development dataset. Then, an independent validation dataset was built from patients admitted during the period of one year later. HF was diagnosed based on the following information in the medical records: clinical syndromes consisting of dyspnea, malaise, edema, or decreased exercise capacity due to the loss of compensation of cardiac pump function, secondary to structural or functional abnormalities of the heart [15].

Patient characteristics, laboratory data, and echocardiographic data were manually extracted from electronic medical records by a hired data collection staff. In addition, diagnosis procedure combination (DPC) data were also added to build a high-quality database in this study. DPC is made up of unified patient clinical information in Japan, patient information including disease name, surgical procedure, various stage classifications, medical expenses, and patients’ medical practice is converted into electronic data, and medical insurance services such as claims are provided in Japan based on this DPC [16]. After verifying consistency between DPC data and medical records data, the database for this study was created. The database construction flow is shown in Supplementary Figure S1 and details of patients information are summarized in Supplementary Table S1.

Figure 1 shows the flowchart of the proposed prognostic prediction system. It mainly consists of predictors’ selection, model development and validation, evaluation from discrimination, calibration, overall aspects [17], and risk stratification.
2.2. Outcome Definition

The endpoint was evaluated as all-cause mortality including both cardiovascular and non-cardiovascular mortality. Cardiovascular mortality was defined as death due to acute myocardial infarction, sudden cardiac death, HF, stroke, cardiovascular procedures, cardiovascular hemorrhage, and other cardiovascular deaths that could not be attributed to non-cardiac causes. Non-cardiovascular mortality was defined as any death that was not thought to be the result of a cardiovascular cause, such as infection and/or malignancy.
2.3. Preprocessing and Statistical Analysis

Candidate predictors were identified by preprocessing and statistical analysis, as previously described [18]. First, covariates that were missing in more than 20% of patients were excluded. As multiple imputation needs to be trained and is hard to converge with a relatively small sample size but a high dimension of variables, in addition, after checking the missing distribution, the missingness distribution seems balanced between death and survival groups as illustrated in Supplementary Table S2, and the continuous and categorical covariates with missing data were imputed using the simple imputation method [19]. Then, covariates significantly associated with mortality were identified by the univariate CPH model and least absolute shrinkage and selection operator regression [20] together. Multicollinearity was assessed and excluded by Pearson’s correlation coefficient between pairs of continuous variables (setting 0.60 as a threshold) as was performed by Mesquita et al. [21]. Thereafter, the remaining covariates were identified as candidate predictors, where continuous predictors were Z-score standardized [22] when inputting to models. Available covariates were presented as mean ± standard deviation or frequency (percentage) in view of the covariates’ type. For group comparison, a two-tailed, unpaired Student’s t-test was used to assess the difference of continuous covariates with normal distribution, and a Mann–Whitney test was employed for skewed continuous covariates, where normality was tested using the Shapiro–Wilk test. Categorical data were compared using Pearson’s Chi-square test or Fisher’s exact test, as appropriate. A p value < 0.05 was considered statistically significant. Data preprocessing was performed using Python (Python Software Foundation, Beaverton, OR, USA; version 3.7.7), and statistical analysis was conducted using R (R Foundation for Statistical Computing, Vienna, Austria; version x64 3.6.0).

2.4. Model Development and Validation

The proposed RNNSurv’s input includes two categories of candidate predictors: invariant (collected once) and time-varying (collected at both admission and discharge) with different input strategies. RNNSurv consists of two branches as shown in Supplementary Figure S2. The first is an RNN layer with inputs of time-step dynamic predictors (at admission and discharge). The second branch is an FC layer with inputs of invariant predictors. Each FC layer connects with a ReLu activation function and batch normalization, and is trained with a dropout strategy to reduce the risk of overfitting. Then, outputs of the two branches are concentrated as a vector and input to the output layer. The detailed parameters of the RNNSurv are illustrated in Supplementary Table S3 after trial and error. RNNSurv was trained with an Adam optimizer, a learning rate of 0.05, and a training batch size of 64. Early termination was activated if the loss function did not decrease after 20 consecutive epochs; otherwise, the training process continued to 1000 epochs. The model was developed and internally validated by a 10-fold cross validation strategy on a development dataset, which consisted of data from patients admitted between 7 April 2016 and 17 March 2019. Simultaneously, back-elimination was employed to further improve performance and to reduce required predictors. In detail, the candidate predictor that had the greatest negative impact on testing performance (C-index) was deleted, and the process was repeated until no further predictor deletion would improve testing performance. After the model was developed, it was validated on an independent dataset, of which data were obtained in the same way as the development dataset but collected from patients admitted between 20 March 2019 and 16 March 2020. The detailed development and validation processes are shown in Figure 2.
In addition, a DeepSurv model [9] and a multivariate CPH model [6] were also developed and temporally validated for performance comparison. To avoid overfitting, the DeepSurv model employed a shallow structure with two FC layers. The first FC layer was followed by a ReLU activation function and batch normalization and trained using the dropout strategy as shown in Supplementary Figure S3. Its training configurations were the same as those of RNNSurv. The CPH model employed a penalty with 0.05 to the size of the coefficients during regression. This improved the stability of estimates and avoided convergence failure. The initial inputs, i.e., the candidate predictors obtained above, of the three models were the same. Because the DeepSurv and CPH models cannot capture temporal features by themselves, a covariate separately measured at admission and discharge would be regarded as two independent predictors. For example, heart rate (HR) was measured at both admission (HR_A) and discharge (HR_D), resulting in two predictors: HR_A and HR_D for DeepSurv and CPH. However, as RNNSurv could capture temporal information among time steps, it would regard the HR as one predictor but with two time steps (admission and discharge). After back-elimination, the optimal predictor sets may vary with models due to differences in algorithms.

2.5. Performance Evaluation

Discrimination performance of models was evaluated using Harrell’s C-index [23] and cumulative/dynamic time-dependent area under the receiver operating characteristic curve (AUC) [24]. Higher C-index and time-dependent AUC values indicate better discrimination. Calibration was evaluated at 1 and 2 years during follow-up using a calibration plot [25] and a Hosmer–Lemeshow test simultaneously. If the calibration plot lies on a 45-degree line, the calibration performance is perfect. Furthermore, the Brier score [26] was used for overall performance evaluation, where a score closer to 0 indicates better performance. Apart from the abovementioned measures, the models’ prediction performance was further evaluated in view of their risk stratification ability. The 20% of patients with lower predicted survival probabilities were considered at high risk of mortality [8]. Then, survival curves of high-risk and the other 80% patients (non-high-risk or low-risk) were checked using a Kaplan–Meier estimator and a log-rank test.

3. Results

3.1. Characteristics of Patients and Candidate Predictors

In total, 562 patients were included in the development dataset. The average age was 78 years and 45.7% of them were female. During follow-up of $30.9 \pm 13.7$ months, 81 (14.4%) patients died. Patients who died were older, with more prior hospital admissions, had a heavier burden on independence in daily life for the elderly with cognitive impairment (IDL) and activities of daily living (ADL), and were more likely to have chronic kidney
disease (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m\(^2\)), compared with patients who survived, as illustrated in Supplementary Table S1. The validation dataset included 168 patients of whom 26 (16.7%) patients died. Most characteristics were comparable between patients in the development and validation datasets, but patients in the validation dataset had lower body mass index (BMI), CHA\(_2\)DS\(_2\)-VAS\(_2\) score, and right ventricular systolic pressure (RVSP). The mortality between the development and validation datasets had no significant difference (14.4% vs. 16.7%, respectively, \(p = 0.551\)). The detailed comparison is illustrated in Supplementary Table S4.

After candidate predictor selection, age, length of stay, prior admission times, ischemic heart disease (IHD), New York Heart Association (NYHA) at discharge, frailty class, CHADS\(_2\), left ventricular ejection fraction (LVEF), mitral regurgitation (MR), tricuspid regurgitation (TR), RVSP, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB), NT-proB-type natriuretic peptide (NT-proBNP), hemoglobin (HGB), and time-varying covariates including eGFR, systolic blood pressure (SBP), diastolic blood pressure (DBP), HR, and low ADL were identified as initial candidate predictors for all-cause mortality, as illustrated in Supplementary Table S5.

### 3.2. Discrimination Evaluation

Candidate predictors were used to build initial models (RNNSurv, DeepSurv, and CPH). After back-elimination, the final predictors and C-index were obtained, as illustrated in Table 1. Models were internally validated by 10-fold cross validation and then temporally validated. Once the final used predictors were determined by back-elimination, models were trained on all of the data of the development dataset and then validated on the validation dataset. In 10-fold cross validation, the proposed RNNSurv achieved a 0.807 ± 0.057 (mean ± standard derivation) testing C-index on the development dataset and a C-index of 0.809 ± 0.022 on the validation dataset, whereas those of the DeepSurv model were 0.783 ± 0.066 and 0.762 ± 0.022, respectively, and those of the CPH model were 0.754 ± 0.069 and 0.764 ± 0.002, respectively. An ANOVA test with the Tukey method confirmed that the C-index of RNNSurv was significantly different from that of CPH and DeepSurv (RNNSurv vs. DeepSurv: \(p < 0.001\); RNNSurv vs. CPH: \(p < 0.001\)). When RNNSurv, DeepSurv, and CPH were trained on all of the data of the development dataset, the validation C-indexes were 0.839, 0.755, and 0.764, respectively. In terms of predictors, the three models perform both generalizability and specificity. For example, all three models take age, length of stay, NT-proBNP, etc., as the predictors; while some predictors are model-specific, such as TR and IDL.

| Model  | Model Development (10-Fold Cross Validation) | Validation  | All of the Data | Predictors                                                                 |
|--------|---------------------------------------------|-------------|----------------|---------------------------------------------------------------------------|
| RNNSurv | Train: 0.820 ± 0.022 Test: 0.807 ± 0.057  | 0.809 ± 0.022 | Development: 0.890 Validation: 0.839 | Invariant predictors: Age, length of stay, IHD, NYHA at discharge, frailty, LVEF, TR, ACEi/ARB, NT-proBNP, HGB; Time-varying predictors: eGFR, SBP, DBP, HR, low ADL |
|        |                                             | (RNNSurv vs. DeepSurv: \(p < 0.001\); (RNNSurv vs. CPH: \(p < 0.001\)) |                                             |                                                                             |
| DeepSurv | Train: 0.818 ± 0.033 Test: 0.783 ± 0.066  | 0.762 ± 0.022 | Development: 0.872 Validation: 0.755 | Age, length of stay, IHD, LVEF, RVSP, HGB, ACEi/ARB, IDL, NT-proBNP, (NYHA, eGFR, SBP, DBP, HR, low ADL) at discharge |
|        |                                             |             |                                             |                                                                             |
| CPH    | Train: 0.768 ± 0.010 Test: 0.754 ± 0.069  | 0.764 ± 0.002 | Development: 0.767 Validation: 0.762 | Length of stay, IDL, ACEi/ARB, NT-proBNP, (NYHA, eGFR, SBP, low ADL) at discharge |

In addition to the C-index, the time-dependent AUCs of every 3 months are visualized in Figure 3. The upper boundary was set at 4 years for the development dataset and 2 years for the validation dataset to avoid high censoring rates at later follow-up times.
The proposed model outperformed DeepSurv and CPH on both the development (Figure 3a) and validation datasets (Figure 3b).

Figure 3. Time-dependent AUCs of models on development dataset (a) and validation dataset (b).

3.3. Calibration Evaluation

The calibration plots of the three models are shown in Figure 4. All three models fit well to a 45-degree line on the development dataset, indicating almost perfect calibration ability. On the validation dataset, the calibration plot of the proposed model seemed better than those of the other models. However, the three models showed a worse calibration ability on the validation dataset than the development dataset and the reason for this phenomenon has been explained by Park et al. [17]—if the sample size is small, few individuals will be included in subgroups. In this case, calibration analysis in view of the calibration plot and the statistical test are not robust or powerful enough.

Figure 4. Cont.
3.4. Overall Evaluation

The Brier score of the proposed model was smaller than those of DeepSurv and CPH on both the development and the validation datasets, as shown in Figure 5, indicating a better overall performance. In detail, the mean ± standard deviation of Brier scores of RNNSurv, DeepSurv, and CPH were 0.054 ± 0.017, 0.066 ± 0.020, and 0.080 ± 0.025 on the development dataset, and 0.099 ± 0.039, 0.107 ± 0.039, and 0.112 ± 0.040 on the validation dataset, respectively.

Figure 4. Calibration evaluation of RNNSurve (a,b), DeepSurve (c,d), and CPH model (e,f).

Figure 5. Brier scores of models on development dataset (a) and validation dataset (b).
3.5. Risk Stratification

The prediction performance was further evaluated in view of the ability of risk stratification. Kaplan–Meier survival curves of high-risk and other (non-high-risk or low-risk) patients stratified by the three models are visualized in Figure 6. Compared with DeepSurv (Figure 6c,d) and CPH (Figure 6e,f), the survival curves of high-risk patients stratified by the proposed RNNSurv (Figure 6a,b) had more obvious differences from other patients on both the development and validation datasets, indicating a better ability of risk stratification. Mortality in the high-risk patient group and other or low-risk patient group stratified by RNNSurv had a significant difference (51.8% vs. 5.1%, \( p < 0.001 \) on the development dataset; 48.5% vs. 8.9%, \( p < 0.001 \) on the validation dataset). Patients with high risk of all-cause mortality were older, were more often female, had a heavier burden on their medical history in terms of IHD and vascular disease (VD), had a longer length of stay and severe HF symptoms assessed by NYHA and heavier burden on daily activities, and were more likely to have chronic kidney diseases compared with low-risk patients. Details are illustrated in Supplementary Table S6.

Figure 6. Risk stratification by the RNNSurve (a,b), DeepSurve (c,d), and CPH (e,f) models.
Additionally, significant risk and protective factors varied across all patients and high-risk patients only. Based on the results of univariate CPH analysis, in the patient group with a high risk of all-cause mortality, NYHA class (hazard ratio: 1.73 (95%CI 1.21–2.46), \( p = 0.002 \)), low ADL (hazard ratio: 2.38 (95%CI 1.29–4.37), \( p = 0.005 \)), creatinine (hazard ratio: 1.12 (95%CI 1.03–1.22), \( p = 0.011 \)), and HR (hazard ratio: 1.02 (95%CI 1.00–1.03), \( p = 0.049 \)) were significant risk factors, while protective factors were female (hazard ratio: 0.53 (95%CI 0.31–0.88), \( p = 0.015 \)), direct oral anticoagulants/Warfarin usage (DOACWFuse) (hazard ratio: 0.47 (95%CI 0.27–0.83), \( p = 0.009 \)), SBP (hazard ratio: 0.98 (95%CI 0.96–0.99), \( p < 0.001 \)), and DBP (hazard ratio: 0.97 (95%CI 0.95–0.998), \( p = 0.031 \)) (see Supplementary Table S7). However, in addition to the above significant factors, age (hazard ratio: 1.04 (95%CI 1.02–1.06), \( p < 0.001 \)), CHA\(_2\)DS\(_2\)-VASc (hazard ratio: 1.15 (95%CI 1.02–1.30), \( p = 0.024 \)), eGFR (hazard ratio: 0.98 (95%CI 0.96–0.99) at admission, \( p < 0.001 \); 0.96 (95%CI 0.94–0.97) at discharge, \( p < 0.001 \)), etc., were also significantly associated with mortality in all patient groups (Supplementary Table S5).

4. Discussion

In this study, an RNN-based prognostic prediction model for patients with HF was developed and temporally validated. This model can consider time-varying covariates, which imply the course of disease (improving or worsening), and learn temporal information from these covariates for decision-making, while DeepSurv and CPH have no such ability. The proposed model achieved better prediction performance than DeepSurv and CPH in view of discrimination, calibration, and ability of risk stratification.

The multivariate CPH model is the most-used survival model to fit the relationship between patients’ covariates and outcomes [27]. However, its prediction ability may be limited by linear assumptions. Recently, Bazoukis et al. concluded that machine learning methods were important and effective for diagnosis, management, and prediction of outcomes in HF patients [28]. In addition, instead of expensive imaging measurement, Liu et al. reported a cheap method to estimate LVEF achieved by machine learning algorithms [29]. Coincidentally, a modern CPH feed-forward deep neural network model (DeepSurv) was proposed as an alternative method for survival or risk prediction [8,9]. The neural network-based model could learn and capture more complex and abstract features and feature combinations from input covariates by nonlinear activation functions in layers. Both CPH and DeepSurv assume that covariates or predictors are invariant. However, some covariates are time-varying due to treatments such as polypharmacy in real-world situations, which are informative and reflect the course of disease. These temporal features should be considered in prediction models. Conversely, the proposed RNN-based prediction model could “remember” previous information and use it for current decision-making; therefore, it naturally accepts and considers time-varying predictors by serially learning.

The proposed model identifies and uses predictors that are easily obtained by routine examination and are measured at admission and discharge. Most of these predictors are previously reported prognostic markers. Specifically, age, NYHA, LVEF, ACEi/ARB, HGB, and SBP were previously identified as predictors in the Seattle Heart Failure Model to predict 1-, 2-, and 3-year survival rates for patients with HF [30]. NT-proBNP was used as one of the predictors for clinical outcomes in patients with HFrEF [31]. Although eGFR was widely reported as strongly associated with outcome in HF, few studies used it as a predictor [32]. In our study, eGFR was identified as a predictor.

The proposed model has a considerable ability of risk stratification, especially in identifying patients who have high risk of mortality. Patients with high risk of all-cause mortality are much older. As reported by Gustafsson et al., elderly patients hospitalized with HF had a very critical prognosis [33]. NYHA classification is generally used to estimate HF symptoms, and it was reported to be a significant predictor of all-cause mortality [34]. In our study, NYHA was identified as a predictor of all-cause mortality as well, and a greater proportion of patients with high risk of all-cause mortality had high NYHA (e.g., NYHA III, IV). Shamagian et al. defined patients with eGFR < 30 mL/min/1.73 m\(^2\) as having severe
renal failure, which was reported to be a strong predictor of mortality, and these patients had significantly poor survival rates [35]. In our study, eGFR was a significant predictor for all-cause mortality. The proportion of patients with eGFR < 30 mL/min/1.73 m$^2$ in the high-risk group was about two or three times that of the non-high-risk group. It was reported that higher NT-proBNP levels were associated with higher incidences of all-cause mortality [36], which is consistent with our study. Dunlay et al. reported that mortality increased with increasing ADL difficulty [37] and low admission ADL was reported to be associated with cardiovascular mortality [38]. In this study, low ADL was a predictor for all-cause mortality and patients with high risk of all-cause mortality more often had low ADL at both admission and discharge. A systematic review and meta-analysis conducted by Lakhan et al. concluded that high C-reactive protein (CRP) was significantly associated with an increased risk of all-cause mortality and sometimes related to a greater risk of long-term adverse cardiovascular outcomes for patients with HF with preserved ejection fraction [39]. In this study with mixed cases, patients with high risk of all-cause mortality had significantly higher CRP than patients in the low-risk group.

Notably, significant risk and protective factors affecting survival or mortality are risk level-specific. Therefore, risk stratification or identifying patients at high risk are crucial to guide precision medicine and clinical strategies such as individually management and treatment. Based on the possible survival duration or probability of mortality after discharge, it is helpful in determining if or when the prevention treatment for high-risk patients should be introduced and determining if an early discharge could be conducted for low-risk patients to save costs and medical resources. Moreover, covariate value collected at discharge is more likely to perform a significant risk or protective effect on prognosis than the one collected at admission, indicating that covariates collected at discharge are more strongly associated with prognostic outcomes than ones collected at admission, and should be given more attention.

Limitations of the presented study are noted as follows. First, the proposed model was developed on a single-center dataset. Although a temporal validation, which is considered intermediate between internal and external validation, was conducted based on the TRIPOD report [13], an external validation is needed, such as conducting the validation on multiple centers and populations for further performance confirmation. Second, some predictors used in previously developed prediction models were not recorded, such as lymphocyte counts, uric acid, and sodium levels, which were used in the Seattle Heart Failure Model; therefore, performance comparison with these models is limited. Third, some covariates have missing data in varying proportions (>20%), limiting their inclusion in this study and prediction ability. Finally, the confirmation of event and survival information were determined by DPC data and medical records only, and thus it is possible that the event after discharge has not been fully confirmed or captured.

5. Conclusions

The proposed RNN-based risk prediction model for patients with HF demonstrated better performance than conventional statistical-based (CPH) and classical deep learning-based (DeepSurv) models. The model considers and accepts time-varying covariates, and in this way, it captures temporal information existing in a real-world situation. Risk and protective factors that are significantly associated with mortality are specific to risk levels, highlighting the demand for individual-specific clinical strategy instead of a uniform one-for-all strategy.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics12122947/s1, Table S1. Characteristics of Patients with Heart Failure for Model Development; Table S2. Comparison of Covariate Missing between Death and Survival Patient groups in Development Dataset; Table S3. Parameters of RNNSurv; Table S4. Comparison Between Patients in Development and Validation Datasets; Table S5. Candidate Predictors for All-cause Mortality; Table S6. Comparison Between High- and Low-Risk Patients Stratified by RNNSurv for All-Cause Mortality; Table S7. Univariate analysis for High-risk group (All-
cause Mortality); Figure S1. Database construction flowchart; Figure S2. Structure of the proposed RNNSurv; Figure S3. Structure of DeepSurv.

**Author Contributions:** Conceptualization, K.N., X.Z. (Xue Zhou) and X.Z. (Xin Zhu); methodology, X.Z. (Xue Zhou), M.H. and X.Z. (Xin Zhu); software, X.Z. (Xue Zhou), M.H. and X.Z. (Xin Zhu); validation, K.N., X.Z. (Xue Zhou) and X.Z. (Xin Zhu); formal analysis, K.N., X.Z. (Xue Zhou) and X.Z. (Xin Zhu); investigation, K.N., X.Z. (Xue Zhou) and X.Z. (Xin Zhu); resources, K.N., N.S., Y.T., Y.E., H.H., M.N. (Mahito Noro), K.S., M.M. and M.N. (Masato Nakamura); data curation, K.N., X.Z. (Xue Zhou), N.S., Y.T., Y.E., H.H., M.N. (Mahito Noro), K.S., M.H., M.M., M.N. (Masato Nakamura) and X.Z. (Xin Zhu); writing—original draft preparation, K.N., X.Z. (Xue Zhou) and X.Z. (Xin Zhu); writing—review and editing, K.N., X.Z. (Xue Zhou), N.S., Y.T., Y.E., H.H., M.N. (Mahito Noro), K.S., M.H., M.M., M.N. (Masato Nakamura) and X.Z. (Xin Zhu); visualization, X.Z. (Xue Zhou) and X.Z. (Xin Zhu); supervision, K.N. and X.Z. (Xin Zhu); project administration, K.N. and X.Z. (Xin Zhu); funding acquisition, K.N. and X.Z. (Xin Zhu). All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Japan Society for the Promotion of Science Kakenhi Basic Research Fund C 21K10287 and Competitive Research Fund of The University of Aizu, 2022-P-12.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board and Ethics Committee of Ohashi Medical Center, School of Medicine, Toho University (No. H19031).

**Informed Consent Statement:** Patient consent was waived for this study in accordance with the national legislation and the institutional requirements.

**Data Availability Statement:** The data used in this article are not readily available because of the restrictions of the Institutional Review Board. Requests to access the datasets should be directed to the corresponding authors.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

The following abbreviations are used in this manuscript:

- **ACEi/ARB** Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
- **ADL** Activities of daily living
- **AUC** Area under receiver operating characteristic curve
- **BMI** Body mass index
- **CPH** Cox proportional hazard
- **CRP** C-reactive protein
- **DBP** Diastolic blood pressure
- **DPC** Diagnosis procedure combination
- **eGFR** Estimated glomerular filtration rate
- **FC** Fully connected
- **HF** Heart failure
- **HGB** Hemoglobin
- **HR** Heart rate
- **HR_A** HR measured at admission
- **HR_A** HR measured at discharge
- **IHD** Ischemic heart disease
- **IDL** Independence in daily life for the elderly with cognitive impairment
- **LVEF** Left ventricular ejection fraction
- **MR** Mitral regurgitation
- **NT-proBNP** NT-proB-type natriuretic peptide
- **NYHA** New York Heart Association
- **RNN** Recurrent neural network
- **RVSP** Right ventricular systolic pressure
- **SBP** Systolic blood pressure
- **TR** Tricuspid regurgitation
- **VD** Vascular disease
References

1. Roger, V.L. Epidemiology of heart failure: A contemporary perspective. Circ. Res. 2021, 128, 1421–1434. [CrossRef]
2. McMurray, J.J.; Stewart, S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000, 83, 596–602. [CrossRef]
3. Okura, Y.; Ramadán, M.M.; Ohno, Y.; Mitsuma, W.; Tanaka, K.; Ito, M.; Suzuki, K.; Tanabe, N.; Kodama, M.; Aizawa, Y. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ. J. 2008, 72, 489–491. [CrossRef]
4. Hamaguchi, S.; Kinugawa, S.; Tsuchihashi-Makaya, M.; Goto, D.; Yamada, S.; Yokoshiki, H.; Tsutsui, H. Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure—A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (ICARE-J). J. Cardiol. 2013, 62, 95–101. [CrossRef]
5. Kanaoka, K.; Okayama, S.; Nakai, M.; Sumita, Y.; Nishimura, K.; Kawakami, R.; Okura, H.; Miyamoto, Y.; Yasuda, S.; Tsutsui, H.; et al. Hospitalization costs for patients with acute congestive heart failure in Japan. Circ. J. 2019, 83, 1025–1031. [CrossRef]
6. Cox, D.R. Regression models and life-tables. J. R. Stat. Soc. Ser. B (Methodol.) 1972, 34, 187–220. [CrossRef]
7. Kim, D.W.; Lee, S.; Kwon, S.; Nam, W.; Cha, I.; Kim, H.J. Deep learning-based survival prediction of oral cancer patients. Sci. Rep. 2019, 9, 6994. [CrossRef]
8. Hathaway, Q.A.; Yanamala, N.; Budoff, M.J.; Sengupta, P.P.; Zeb, I. Deep neural survival networks for cardiovascular risk prediction: The Multi-Ethnic Study of Atherosclerosis (MESA). Comput. Biol. Med. 2021, 139, 104983. [CrossRef]
9. Katzman, J.L.; Shaham, U.; Cloninger, A.; Bates, J.; Jiang, T.; Kluger, Y. DeepSurv: Personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med. Res. Methodol. 2018, 18, 24. [CrossRef]
10. She, Y.; Jin, Z.; Wu, J.; Deng, J.; Zhang, L.; Su, H.; Jiang, G.; Liu, H.; Xie, D.; Cao, N.; et al. Development and validation of a deep learning model for non–small cell lung cancer survival. JAMA Netw. Open. 2020, 3, e205842. [CrossRef]
11. Liang, W.; Yao, J.; Chen, A.; Lv, Q.; Zanin, M.; Liu, J.; Wong, S.; Li, Y.; Lu, J.; Liang, H.; et al. Early triage of critically ill COVID-19 patients using deep learning. Nat. Commun. 2020, 11, 3543. [CrossRef]
12. Fisher, L.D.; Lin, D.Y. Time-dependent covariates in the Cox proportional-hazards regression model. Annu. Rev. Public Health 1999, 20, 145–157. [CrossRef]
13. Moons, K.G.M.; Altman, D.G.; Reitsma, J.B.; Ioannidis, J.P.A.; Macaskill, P.; Steyerberg, E.W.; Vickers, A.J.; Ransohoff, D.F.; Collins, G.S. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): Explanation and elaboration. Ann. Intern. Med. 2015, 162, W1–W73. [CrossRef]
14. Zhou, X.; Nakamura, K.; Sahara, N.; Asami, M.; Toyoda, Y.; Enomoto, Y.; Hara, H.; Noro, M.; Sugi, K.; Moroi, M.; et al. Exploring and identifying prognostic phenomena of patients with heart failure guided by explainable machine learning. Life 2022, 12, 776. [CrossRef]
15. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Čelutkienė, J.; Chioncel, O.; Cleland, J.G.F.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021, 42, 3599–3726.
16. Kodama, K.; Sakamoto, T.; Kubota, T.; Takimura, H.; Hongo, H.; Chikashima, H.; Shibasaki, Y.; Yada, T.; Node, K.; Nakayama, T.; et al. Construction of a heart failure database collating administrative claims data and electronic medical record data to evaluate risk factors for in-hospital death and prolonged hospitalization. Circ. Rep. 2019, 1, 582–592. [CrossRef]
17. Park, S.Y.; Park, J.E.; Kim, H.; Park, S.H. Review of statistical methods for evaluating the performance of survival or other time-to-event prediction models (from conventional to deep learning approaches). Korean J. Radiol. 2021, 22, 1697–1707. [CrossRef]
18. Zhou, X.; Nakamura, K.; Sahara, N.; Takagi, T.; Toyoda, Y.; Enomoto, Y.; Hara, H.; Noro, M.; Sugi, K.; Moroi, M.; et al. Deep learning-based recurrence prediction of atrial fibrillation after catheter ablation. Circ. J. 2022, 86, 299–308. [CrossRef]
19. Ng, K.; Steinhubl, S.R.; deFilippi, C.; Dey, S.; Stewart, W.F. Early detection of heart failure using electronic health records: Practical implications for time before diagnosis, data diversity, data quantity, and data density. Circ. Cardiovasc. Qual. Outcomes 2016, 9, 649–658. [CrossRef]
20. Shibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. B 1996, 58, 267–288. [CrossRef]
21. Mesquita, J.; Ferreira, A.M.; Cavaco, D.; Moscoso Costa, F.; Carmo, P.; Marques, H.; Morgado, F.; Mendes, M.; Adragão, P. Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure–ATLAS score. EP Eur. 2018, 20, 428–435. [CrossRef]
22. Shalabi, L.A.; Shaaban, Z.; Kasasbeh, B. Data mining: A preprocessing engine. J. Comput. Sci. 2006, 2, 735–739. [CrossRef]
23. Harrell, F.E.; Califf, R.M.; Pryor, D.B.; Lee, K.L.; Rosati, R.A. Evaluating the yield of medical tests. JAMA 1982, 247, 2543–2546. [CrossRef]
24. Lambert, J.; Chevret, S. Summary measure of discrimination in survival models based on cumulative/dynamic time-dependent ROC curves. Stat. Methods Med. Res. 2016, 25, 2088–2102. [CrossRef]
25. Park, S.H.; Han, K. Methodological guide for evaluating clinical performance and effect of artificial intelligence technology for medical diagnosis and prediction. Radiology 2018, 286, 800–809. [CrossRef]
26. Brier, G.W. Verification of forecasts expressed in terms of probability. Mon. Weather Rev. 1950, 78, 1–3. [CrossRef]
27. Wang, P.; Li, Y.; Reddy, C.K. Machine learning for survival analysis: A survey. ACM Comput. Surv. 2019, 51, 1–36. [CrossRef]
28. Bazoukis, G.; Stavrakis, S.; Zhou, J.; Bollepalli, S.C.; Tse, G.; Zhang, Q.; Singh, J.P.; Armoundas, A.A. Machine learning versus conventional clinical methods in guiding management of heart failure patients—a systematic review. Heart Fail. Rev. 2021, 26, 23–34. [CrossRef]
29. Liu, S.; Yang, Z.; Pan, K.; Zhu, X.; Chen, W. Estimation of left ventricular ejection fraction using cardiovascular hemodynamic parameters and pulse morphological characteristics with machine learning algorithms. *Nutrients* **2022**, *14*, 4051. [CrossRef]

30. Levy, W.C.; Mozaffarian, D.; Linker, D.T.; Sutradhar, S.C.; Anker, S.D.; Cropp, A.B.; Anand, I.; Maggioni, A.; Burton, P.; Sullivan, M.D.; et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. *Circulation* **2016**, *113*, 1424–1433. [CrossRef]

31. Mentz, R.J.; Mulder, H.; Mosterd, A.; Sweitzer, N.K.; Seni, M.; Butler, J.; Ezekowitz, J.A.; Lam, C.S.P.; Pieske, B.; Fonikowski, P.; et al. Clinical outcome predictions for the VericiguAt Global Study in subjects with heart failure with reduced ejection fraction (VICTORIA) trial: VICTORIA outcomes model. *J. Card. Fail.* **2021**, *27*, 949–956. [CrossRef]

32. Simpson, J.; Jhund, P.S.; Lund, L.H.; Padmanabhan, S.; Claggett, B.L.; Shen, L. Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure. *JAMA Cardiol.* **2020**, *5*, 432–441. [CrossRef] [PubMed]

33. Mentz, R.J.; Mulder, H.; Mosterd, A.; Sweitzer, N.K.; Seni, M.; Butler, J.; Ezekowitz, J.A.; Lam, C.S.P.; Pieske, B.; Fonikowski, P.; et al. Clinical outcome predictions for the VericiguAt Global Study in subjects with heart failure with reduced ejection fraction (VICTORIA) trial: VICTORIA outcomes model. *J. Card. Fail.* **2021**, *27*, 949–956. [CrossRef]

34. Kajimoto, K.; Sato, N.; Investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) Registry. Sex differences in New York Heart Association functional classification and survival in acute heart failure patients with preserved or reduced ejection fraction. *Can. J. Cardiol.* **2020**, *36*, 30–36. [CrossRef] [PubMed]

35. Shamagian, L.G.; Román, A.V.; Pérez, M.P.; Otero, I.G.; Lamela, A.V.; González-Juanatey, J.R. Renal failure is an independent predictor of mortality in hospitalized heart failure patients and is associated with a worse cardiovascular risk profile. *Rev. Esp. Cardiol.* **2006**, *59*, 99–108. [CrossRef]

36. Rudolf, H.; Mücke, A.; Trampisch, H.J.; Scharnagl, H.; März, W.; Kara, K. NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study. *Int. J. Cardiol. Heart Vasc.* **2020**, *29*, 100553. [CrossRef] [PubMed]

37. Dunlay, S.M.; Manemann, S.M.; Chamberlain, A.M.; Cheville, A.L.; Jiang, R.; Weston, S.A.; Roger, V.L. Activities of daily living and outcomes in heart failure. *Circ. Heart Fail.* **2015**, *8*, 261–267. [CrossRef]

38. Gohbara, M.; Nishimura, K.; Nakai, M.; Sumita, Y.; Endo, T.; Matsuzawa, Y.; Konishi, M.; Kosuge, M.; Ebina, T.; Tamura, K.; et al. Low activities of daily living associated with increased cardiovascular disease mortality in Japan: Analysis of health records from a Nationwide Claim-Based Database, JROAD-DPC. *Circ. Rep.* **2019**, *1*, 20–28. [CrossRef] [PubMed]

39. Lakhani, I.; Wong, M.V.; Huang, J.K.F.; Gong, M.; Waleed, K.B.; Xia, Y.; Lee, S.; Roever, L.; Liu, T.; Tse, G.; et al. Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: A systematic review and meta-analysis. *Heart Fail. Rev.* **2021**, *26*, 1141–1150. [CrossRef] [PubMed]